CellVax
Cellvax | Preclinical CRO | Expertise in Oncology and Osteoarthritis.
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
% growth | 20 % | (26 %) | (83 %) | 413 % | 33 % | - | 80 % |
EBITDA | <1m | <1m | (<1m) | <1m | - | - | - |
% EBITDA margin | 39 % | 38 % | (588 %) | 40 % | - | - | - |
Profit | <1m | <1m | (<1m) | <1m | - | - | - |
% profit margin | 39 % | 64 % | (451 %) | 47 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | - | ||
€260k | Grant | ||
Total Funding | €260k |
Related Content
Recent News about CellVax
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.